Modelling α-Synuclein Aggregation and Neurodegeneration with Fibril Seeds in Primary Cultures of Mouse Dopaminergic Neurons

Cells. 2022 May 13;11(10):1640. doi: 10.3390/cells11101640.

Abstract

To model α-Synuclein (αS) aggregation and neurodegeneration in Parkinson's disease (PD), we established cultures of mouse midbrain dopamine (DA) neurons and chronically exposed them to fibrils 91 (F91) generated from recombinant human αS. We found that F91 have an exquisite propensity to seed the aggregation of endogenous αS in DA neurons when compared to other neurons in midbrain cultures. Until two weeks post-exposure, somal aggregation in DA neurons increased with F91 concentrations (0.01-0.75 μM) and the time elapsed since the initiation of seeding, with, however, no evidence of DA cell loss within this time interval. Neither toxin-induced mitochondrial deficits nor genetically induced loss of mitochondrial quality control mechanisms promoted F91-mediated αS aggregation or neurodegeneration under these conditions. Yet, a significant loss of DA neurons (~30%) was detectable three weeks after exposure to F91 (0.5 μM), i.e., at a time point where somal aggregation reached a plateau. This loss was preceded by early deficits in DA uptake. Unlike αS aggregation, the loss of DA neurons was prevented by treatment with GDNF, suggesting that αS aggregation in DA neurons may induce a form of cell death mimicking a state of trophic factor deprivation. Overall, our model system may be useful for exploring PD-related pathomechanisms and for testing molecules of therapeutic interest for this disorder.

Keywords: Parkinson disease; cell culture model; dopamine neurons; fibril seeds; neurodegeneration; protein aggregation; α-Synuclein.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Dopamine / metabolism
  • Dopaminergic Neurons / metabolism
  • Mesencephalon / metabolism
  • Mice
  • Parkinson Disease* / metabolism
  • alpha-Synuclein* / metabolism

Substances

  • alpha-Synuclein
  • Dopamine

Grants and funding

This work was carried out in the context of the PD-MitoQUANT project, which received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821522. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme, EFPIA and Parkinson’s UK. The material presented and views expressed here reflect the author’s view and neither IMI nor the European Union, EFPIA or any associated partners are responsible for any use that may be made of the information contained herein. This work also received support from program Investissements d’Avenir [ANR-10-IAIHU-06] and Translational Research Infrastructure for Biotherapies in Neurosciences [ANR-11-INBS-0011-NeurATRIS]. P.P.M. is supported by Association France Parkinson (DOXYPARK).